Clarity Pharmaceuticals Signs Large-Scale Copper-64 Manufacturing Supply Agreement With Theragenics

MT Newswires Live
03/25

Clarity Pharmaceuticals (ASX:CU6) said it has signed a large-scale manufacturing supply agreement for copper-64 with Theragenics, according to a Wednesday Australian bourse filing.

The company said the agreement relates to Theragenics' 134,000-square-foot production facility near Atlanta, Georgia, which houses 14 cyclotrons for centralized, large-scale copper-64 (Cu-64) production.

The supply agreement is ahead of the anticipated commercial launch of Cu-64-SAR-bisPSMA, subject to successful completion of Clarity's phase three registrational trials and subsequent Food and Drug Administration (FDA) new drug application (NDA) approval, the filing added.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10